Fentanyl has become one of the most consequential substances in modern forensic pathology, yet a fundamental question haunts every medicolegal autopsy in which the synthetic opioid appears: did the drug kill the person, and was it taken illicitly at all? A new retrospective study drawing on six years of autopsy records at a high-volume metropolitan forensic institution offers a striking answer that challenges common assumptions. Of 842 fentanyl-positive cases examined between January 2019 and December 2024, the overwhelming majority—731 cases, or 86.8 percent—were classified as consistent with a therapeutic indication, meaning the decedent appears to have been receiving fentanyl legitimately for pain management. Only 68 cases (8.1 percent) showed evidence of non-medical use, while 43 cases (5.1 percent) remained indeterminate. The findings, published in the International Journal of Legal Medicine, underscore a problem that forensic toxicologists have long acknowledged but rarely quantified so systematically: detection of a drug in postmortem samples is not the same as demonstrating that the drug was abused, or that it caused the death.
The interpretive difficulty stems from fentanyl’s peculiar pharmacological profile and its behavior after death. Fentanyl is an extremely potent μ-opioid receptor agonist, roughly 50 to 100 times more powerful than morphine, and therapeutic blood concentrations sit uncomfortably close to concentrations associated with fatal respiratory depression. This narrow window means that even a clinically prescribed dose can be lethal in vulnerable patients, and postmortem redistribution—the migration of the drug between tissues as blood chemistry changes after circulatory arrest—can shift measured concentrations substantially. Earlier work on femoral blood, liver, and cardiac tissue has shown that heart-to-femoral blood ratios can vary widely, making a single postmortem concentration an unreliable indicator of the antemortem dose. In a setting such as the one examined here, where antemortem documentation, prescription records, and clinical histories are often incomplete or unavailable, the task of distinguishing a hospice patient who died of disease while on prescribed fentanyl from a young recreational user who bought illicitly manufactured pills becomes genuinely difficult.
To address this, the research team—Murat Nihat Arslan of Yeditepe University’s Department of Forensic Medicine, together with colleagues from the Council of Forensic Medicine in Istanbul and Bilecik Şeyh Edebali University—applied a structured three-tier classification system to every fentanyl-positive autopsy. Each case was assigned to one of three exposure contexts: consistent with therapeutic indication, non-medical use, or indeterminate. Crucially, the classification relied not on specialized testing but on variables routinely collected during any medicolegal autopsy: the pattern of co-detected substances, markers of clinical intervention such as resuscitation attempts and hospitalization before death, the type of incident that triggered the medicolegal investigation, and external examination findings including needle marks, injection sites, and other body-surface observations. The framework is deliberately designed to be portable—it can be applied in forensic systems anywhere in the world, including those with minimal access to prescription databases or pharmacy records.
The demographic and behavioral contrasts between the two main groups were pronounced. Decedents classified as non-medical users were markedly younger, with a mean age of 32.4 years compared with 45.0 years in the therapeutic group. They were also more predominantly male, at 82.4 percent versus 76.3 percent. When the researchers examined cases that met combined classical forensic criteria—those with external signs of drug use, characteristic death circumstances, and supportive toxicological patterns—the classification system assigned 90.5 percent of them to the non-medical category, suggesting the framework converges well with traditional expert judgment while adding a reproducible structure. This convergence matters for quality assurance in forensic medicine, where death certification of drug-related deaths has historically depended on the individual pathologist’s synthesis of scene investigation, autopsy findings, and toxicology, with documented inconsistency across jurisdictions.
Toxicological co-detection patterns provided some of the study’s most informative signals. Among the non-medical group, amphetamine-type stimulants predominated among co-detected illicit substances—a finding that aligns with regional drug market data but stands in contrast to the opioid-on-opioid polydrug patterns dominating fentanyl mortality statistics in North America. Opioid-on-opioid co-detection was rare in this cohort, a meaningful distinction for interpreting death circumstances. In the United States, the “fourth wave” of the overdose crisis is characterized by fentanyl mixed with stimulants, and before that, fentanyl replacing heroin in illicit supply; in the population studied here, fentanyl appears more often alongside stimulants than alongside other opioids, hinting at a different consumption pattern and possibly different market dynamics than those driving the North American epidemic. Forensic toxicologists elsewhere will need to weigh such regional signatures when extrapolating risk profiles from one country’s data to another’s.
Perhaps the most unexpected finding concerns the body itself as a document of life history. The presence of tattoos and self-inflicted scarring was significantly more frequent in the non-medical group, with a p-value below 0.001. Tattoos, long treated by pathologists primarily as identification aids, have an established literature connecting them with risk-taking behavior, and studies in dermatology and psychology have examined tattoo motivations and regret. Self-mutilation scars carry their own diagnostic weight, having been linked in psychiatric literature to substance dependence, childhood abuse, and alexithymia. By quantifying the association between these visible markers and non-medical fentanyl exposure, the study effectively proposes that careful external examination—something performed in every autopsy, everywhere, at essentially no cost—can carry genuine diagnostic information about exposure context. In resource-limited forensic systems, where advanced molecular testing or comprehensive prescription access may be unavailable, this is a practical and potentially impactful observation.
The temporal trend in the data adds a public-health dimension. Annual fentanyl-positive case numbers increased by 87.3 percent over the six-year study period, a steep rise that mirrors global and regional surveillance reports from the United Nations Office on Drugs and Crime, the International Narcotics Control Board, and the European Union Drugs Agency, all of which have documented fentanyl’s expanding footprint beyond its traditional North American strongholds. Whether this trajectory reflects expanding illicit manufacture, increased therapeutic prescribing, improved screening sensitivity in toxicology laboratories, or a combination of all three cannot be determined from detection counts alone—which is precisely the interpretive trap the study is designed to illuminate. If a laboratory doubles its detection rate by upgrading its mass spectrometry platform, public-health officials reading raw case counts may wrongly infer a doubling of illicit use. Structured classification offers a corrective lens, separating pharmaceutical presence from recreational exposure in a way raw numbers cannot.
The technical underpinnings of postmortem fentanyl interpretation deserve emphasis, because they explain why concentration-based thresholds alone are so treacherous. Reference works cataloging therapeutic and toxic blood concentrations of more than 1,100 drugs provide ranges, but fentanyl’s high potency, short distribution half-life, and extensive tissue binding mean that postmortem concentrations depend heavily on sampling site, postmortem interval, and the dynamics of redistribution as cell membranes lose their integrity. Position papers from forensic bodies, including consensus recommendations for the investigation and certification of opioid-related deaths, explicitly caution against certifying fentanyl toxicity from concentration alone, urging instead a synthesis of scene findings, autopsy pathology, and toxicology. The three-tier framework operationalizes that counsel into a reproducible rubric. Instead of asking “what was the concentration,” it asks “what constellation of independent indicators surrounds this detection”—a question answerable from standard autopsy paperwork.
The authors argue that systematic contextual assessment should become a standard component of medicolegal fentanyl investigation across diverse forensic settings, and the study’s design supports that ambition. Because the classification variables—co-detected substances, clinical intervention markers, incident type, and external findings—are collected in virtually every medicolegal autopsy worldwide, the framework imposes no new burden on pathologists. Its validation in a setting with limited antemortem documentation is particularly valuable, since most published fentanyl research originates in systems, such as the United States, where death certificates and prescription monitoring programs supply rich contextual data. Demonstrating that meaningful stratification is achievable without such infrastructure extends the tool’s relevance to middle- and lower-resource forensic systems where fentanyl’s global spread is now being felt.
The implications ripple outward to epidemiology, clinical practice, and policy. For epidemiologists tracking the diffusion of fentanyl into new markets, distinguishing therapeutic from illicit detections changes the denominator of the epidemic. For clinicians, the finding that nearly 87 percent of fentanyl-positive decedents likely had legitimate indications is a sobering reminder of the drug’s lethality even under medical supervision, particularly in patients with comorbidities, compromised respiratory function, or concurrent central nervous system depressants. For forensic institutions, the study provides a template for internal audit and inter-pathologist consistency. And for the deceased and their families, accurate classification matters at the most human level: the difference between a death certificate recording a complication of palliative cancer therapy and one recording an overdose shapes insurance outcomes, family understanding, and the statistical portrait of a nation’s drug problem. As fentanyl continues its global expansion, tools that convert a bare toxicological positive into a nuanced, evidence-based narrative of exposure will only grow in importance—and this study demonstrates that such tools need not wait for new technology, only for a more disciplined use of what forensic pathologists already see every day.
Subject of Research: Postmortem fentanyl detection in medicolegal autopsies and a structured three-tier framework for classifying exposure context (therapeutic indication, non-medical use, or indeterminate)
Subject of Research: Medicine
Article Title: Fentanyl in forensic autopsies: Trends, circumstances, and toxicological findings
Article References: Arslan, M. N., Çoban, İ., Atan, Y., & Aslıyüksek, H. (2026). Fentanyl in forensic autopsies: Trends, circumstances, and toxicological findings. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-04007-5
Image Credits: AI Generated
DOI: 10.1007/s00414-026-04007-5
Keywords: fentanyl, postmortem toxicology, medicolegal autopsy, exposure context, forensic toxicology, drug-detected death, polysubstance use
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 11, 2026). Forensic autopsies reveal fentanyl death trends and toxicological patterns. Scienmag. https://scienmag.com/forensic-autopsies-reveal-fentanyl-death-trends-and-toxicological-patterns/
Ophelia Keating. “Forensic autopsies reveal fentanyl death trends and toxicological patterns.” Scienmag, 11 September 2026, https://scienmag.com/forensic-autopsies-reveal-fentanyl-death-trends-and-toxicological-patterns/. Accessed 11 September 2026.
Ophelia Keating. “Forensic autopsies reveal fentanyl death trends and toxicological patterns.” Scienmag. September 11, 2026. https://scienmag.com/forensic-autopsies-reveal-fentanyl-death-trends-and-toxicological-patterns/
Copy citation Download RIS
Tags: challenges in determining cause of death with fentanyldistinguishing illicit from medical fentanyl usedistinguishing medical vs illicit fentanyl usefentanyl abuse and therapeutic use in deathsfentanyl detection and death causationfentanyl overdose analysisfentanyl pharmacology and death causationfentanyl-related death trendsforensic autopsy case studies on fentanylforensic autopsy fentanyl trendsforensic toxicology and fentanyl detectionforensic toxicology in opioid overdoseimplications of fentanyl potency in forensic investigationslegal medicine insights into synthetic opioid deathslegitimacy of fentanyl use in autopsiesopioid overdose epidemiology in forensic medicinepharmacological profile of fentanyl in forensic casespostmortem fentanyl detection challengespostmortem fentanyl interpretationpostmortem toxicology interpretation of fentanylretrospective study on fentanyl-related fatalitiessynthetic opioid overdose patternstoxicology patterns in opioid deaths
